The quarter was slightly better on per-share losses but weaker on revenue. Net loss was $0.24 per share versus a published consensus around $0.26, a narrow beat, while collaboration revenue of $1.15 million trailed expectations near $1.32 million.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Collaboration revenue | $1.15M (Statement of Operations) | $1.12M prior year; ~$1.32M published consensus |
| R&D expense | $33.4M (Statement of Operations) | $41.4M prior year |
| G&A expense | $11.0M (Statement of Operations) | $13.1M prior year |
| Net loss | $42.1M (Statement of Operations) | $52.6M prior year |
| Loss per share | $0.24 (Statement of Operations) | $0.41 prior year; ~$0.26 consensus |
| Cash, cash equivalents and investments | $95.1M (Balance Sheet Data) | $177.7M at December 31, 2025 |
Expense control improved the reported loss, but mainly through spending reductions rather than stronger operating momentum. R&D fell 19% and G&A declined 16% year over year, reflecting fewer personnel-related costs, lower stock compensation and lower legal fees—not a meaningful increase in revenue or commercial activity (R&D and G&A Expense disclosures). The lower burn helped the EPS result, but it also reflects a leaner organization as the company advances several programs.
The most important operating update is that PM577a is now moving toward human testing in two regions. U.S. and New Zealand regulatory clearances establish the global Phase 1/2 Wilson disease program, with study startup underway and initial data still targeted for 2027 (Wilson Disease Program update). That is strategically meaningful, but the clearances were announced in June and July 2026, so much of this information was already public by the filing date rather than being a fresh surprise.
PM647’s path to the clinic is clearer after the Beam arbitration, but the near-term catalyst remains execution. The tribunal affirmed Prime’s rights, found no breach and awarded no damages; the company expects to submit an IND and/or CTA in the third quarter of 2026, with initial data in 2027 (Beam Arbitration Resolution and PM647 update). The resolution removes a material legal overhang, although the filing provides no new human efficacy data and the regulatory submission has not yet occurred.
The balance sheet remains the central constraint despite management’s runway claim. Cash, cash equivalents and investments fell to $95.1 million from $177.7 million at year-end—an $82.6 million, or roughly 47%, decline in six months—while the company says funding should last into 2027 (Balance Sheet Data; Liquidity and Capital Resources disclosure). Against the improved quarterly expense profile, that runway is credible only as a near-term statement; advancing PM577a, PM647 and PM359 toward clinical and regulatory milestones will likely keep financing capacity important.
Net read: operationally mixed, with a modest EPS beat offset by a revenue miss and substantial cash depletion. The pipeline developments improve visibility into 2026–2027 milestones, but they largely confirm previously disclosed timing rather than reset expectations sharply higher.
Read the original 8-K on SEC EDGAR ↗